<DOC>
	<DOCNO>NCT00000146</DOCNO>
	<brief_summary>To assess beneficial adverse effect corticosteroid treatment optic neuritis . To determine natural history vision patient suffer optic neuritis . To identify risk factor development multiple sclerosis patient optic neuritis .</brief_summary>
	<brief_title>Optic Neuritis Treatment Trial ( ONTT )</brief_title>
	<detailed_description>Optic neuritis inflammatory disease optic nerve typically affect young adult . Women affect often men . It second glaucoma common acquire optic nerve disorder person young age 50 . In disorder , closely link multiple sclerosis , prognosis visual recovery generally good . However , return visual function almost never complete . After resolution optic neuritis , virtually patient show sign optic nerve damage , symptomatic . Even patient 's acuity recover 20/20 , abnormality frequently remain measure contrast sensitivity , color vision , visual field . Prior Optic Neuritis Treatment Trial ( ONTT ) , well-established guideline treat optic neuritis exist . Although corticosteroid use treat disease , study demonstrate effectiveness satisfactory . Some expert advocate treatment oral prednisone others recommend treatment . Anecdotal report suggest high-dose intravenous corticosteroid might effective . The association optic neuritis multiple sclerosis well establish . Optic neuritis may first manifestation multiple sclerosis , may occur later course . A strong case make `` isolated '' optic neuritis forme fruste multiple sclerosis , base similarity two epidemiologic factor gender , age , geographic distribution , cerebrospinal fluid change , histocompatibility data , magnetic resonance imaging ( MRI ) change , family history . The magnitude risk multiple sclerosis optic neuritis uncertain . Previous study report disparate result , risk report low 13 percent high 88 percent . The importance risk factor age , gender , MRI change predict patient optic neuritis likely develop multiple sclerosis also unclear . The treatment phase study call Optic Neuritis Treatment Trial ( ONTT ) , whereas current long-term followup phase call Longitudinal Optic Neuritis Study ( LONS ) . The study conduct 15 clinical center United States . Resource center include data coordinate center visual field reading center . Patients randomize one three follow treatment group 15 clinical center : - Oral prednisone ( 1 mg/kg/day ) 14 day - Intravenous methylprednisolone ( 250 mg every 6 hour ) 3 day , follow oral prednisone ( 1 mg/kg/day ) 11 day - Oral placebo 14 day Each regimen follow short oral taper . The oral prednisone placebo group double mask , whereas intravenous methylprednisolone group single mask . Baseline test include blood test evaluate syphilis systemic lupus erythematosus , chest x-ray evaluate sarcoidosis , brain MRI scan evaluate change suggestive multiple sclerosis . The rate visual recovery long-term visual outcome assess measure visual acuity , contrast sensitivity , color vision , visual field baseline , seven followup visit first 6 month , yearly . A standardized neurologic examination assessment multiple sclerosis status make baseline , 6 month , yearly .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>The major eligibility criterion enrollment ONTT include follow : Age range 18 46 year Acute unilateral optic neuritis visual symptom 8 day less A relative afferent pupillary defect visual field defect affect eye No previous episode optic neuritis affect eye No previous corticosteroid treatment optic neuritis multiple sclerosis No systemic disease multiple sclerosis might cause optic neuritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>October 2003</verification_date>
</DOC>